Michael Zito Govert
Primary Care · Neptune, NJNPI 1396262200
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,947 of the $60,978 with a category attached, or 68.8%. 17 manufacturers reported payments, led by Gilead at 48.4% of the total. 2025 is the largest year on record at $43,999, more than ten times the $676 reported in 2021. Among primary care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $140.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$30K
- Viiv Healthcare Company$25K
- Theratechnologies Inc.$5K
- Merck$291
- Janssen Products, LP$268
- EMD Serono, Inc.$236
- plus $881 from 11 others
What the payments were for
- Speaking & faculty fees$41,94769%
- Travel & lodging$6,08610%
- Food & beverage$12,35220%
- Education$5931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 149 | $29,505 |
| Viiv Healthcare Company | 175 | $25,099 |
| Theratechnologies Inc. | 25 | $4,698 |
| Merck | 20 | $291 |
| Janssen Products, LP | 3 | $268 |
| EMD Serono, Inc. | 9 | $236 |
| Johnson & Johnson(2 entities) | 14 | $217 |
| Exact Sciences | 4 | $174 |
| AbbVie | 15 | $164 |
| Antares Pharma, Inc. | 5 | $78 |
| Indivior Inc. | 5 | $78 |
| Braeburn Inc. | 3 | $48 |
| Napo Pharmaceuticals Inc | 3 | $44 |
| Alkermes, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,978 in reported general payments places this provider in the 95th percentile of 330 primary care providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 40 | $114,046 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 29 | $107,623 |
| Egrifta SvTesamorelin Acetate | 11 | $105,464 |
| JulucaDolutegravir/Rilpivirine | 24 | $87,443 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $64,378 |
| TivicayDolutegravir Sodium | 15 | $33,883 |
| OzempicSemaglutide | 33 | $28,277 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 52 | $20,526 |
| JanuviaSitagliptin Phosphate | 26 | $17,774 |
| JardianceEmpagliflozin | 18 | $9,568 |
| Testosterone | 15 | $7,035 |
| VascepaIcosapent Ethyl | 11 | $5,117 |
| MovantikNaloxegol Oxalate | 11 | $4,495 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,333 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Juluca, Tivicay | $25,099 | $235,37179 claims |
| GileadBiktarvy, Descovy | $29,505 | $172,00159 claims |
| Theratechnologies Inc.Egrifta Sv | $4,698 | $105,46411 claims |
| Novo NordiskOzempic | $16 | $28,27733 claims |
| MerckJanuvia | $291 | $17,77426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 primary care providers in New Jersey.
Other primary care in Neptune
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
- Shazam BacchusNewark$7K
- Anna NievesBasking Ridge$7K
- Kristen BeerFreehold$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.